Galliprant® (grapiprant tablets)

Treat with Galliprant from the earliest diagnosed stages of canine osteoarthritis (OA)

  • Galliprant is a first-in-class piprant; a non-COX-inhibiting prostaglandin receptor antagonist (PRA)
  • Galliprant does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions¹
  • It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation¹
  • Galliprant is indicated for the control of pain and inflammation associated with osteoarthritis in dogs

In co-promotion with Elanco Animal Health, a division of Eli Lilly and Company. 



  • GALLIPRANT® (grapiprant tablets) is not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose.
  • Do not use in dogs that have a hypersensitivity to grapiprant.
  • If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied.
  • The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease.
  • The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy.

Click here for full prescribing information.


1. Kirkby Shaw, K., Rausch-Derra, L., and Rhodes, L. 2016. “Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation.” Vet. Med. Sci. 2: 3-9. USCACGLP00064